Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-11), Tianjin Pharmaceutical Da Ren Tang Group's 3-1 Month Momentum % is -10.45%.
STU:2TZ's 3-1 Month Momentum % is ranked worse than 67.55% of 1023
companies
in the Drug Manufacturers industry
Industry Median: 3.13
vs STU:2TZ: -10.45
Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Tianjin Pharmaceutical Da Ren Tang Group 3-1 Month Momentum % Related Terms
STU:2TZ vs ZTS: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Tianjin Pharmaceutical Da Ren Tang Group's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tianjin Pharmaceutical Da Ren Tang Group 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tianjin Pharmaceutical Da Ren Tang Group's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Tianjin Pharmaceutical Da Ren Tang Group's 3-1 Month Momentum % falls into.
Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) has a 3-1 Month Momentum % of -10.45% as of Sep. 11, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Tianjin Pharmaceutical Da Ren Tang Group and its competitors. According to the industry distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #691 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 67.5%.
Is Tianjin Pharmaceutical Da Ren Tang Group's 3-1 Month Momentum % too high?
Tianjin Pharmaceutical Da Ren Tang Group's current 3-1 Month Momentum % is -10.45%. Based on the distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #691 out of 1023 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Tianjin Pharmaceutical Da Ren Tang Group has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tianjin Pharmaceutical Da Ren Tang Group's 3-1 Month Momentum % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #691 out of 1023 companies for 3-1 Month Momentum %. This places Tianjin Pharmaceutical Da Ren Tang Group in the lower half of its industry. The industry median 3-1 Month Momentum % is 3.13. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
The median 3-1 Month Momentum % among Drug Manufacturers companies is 3.13, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Tianjin Pharmaceutical Da Ren Tang Group and its competitors. For the Drug Manufacturers industry, the median 3-1 Month Momentum % is 3.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tianjin Pharmaceutical Da Ren Tang Group's current 3-1 Month Momentum % is -10.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tianjin Pharmaceutical Da Ren Tang Group stock overvalued right now?
Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.36, compared to a current price of €2.10 — trading 54.4% above its estimated fair value. The current 3-1 Month Momentum % is -10.45%. Tianjin Pharmaceutical Da Ren Tang Group's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ), the current 3-1 Month Momentum % is -10.45% as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) Overvalued in 2026?
Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group stock appears to be overvalued.
The current stock price of €2.10 is trading 54.4% above its estimated GF Value™ of €1.36.
GuruFocus considers Tianjin Pharmaceutical Da Ren Tang Group to be Significantly Overvalued.
Key valuation signals for STU:2TZ:
3-1 Month Momentum %: -10.45%
GF Value™: €1.36 vs. price of €2.10 (54.4% above fair value)
No single metric tells the full story. See the STU:2TZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company is engaged in the production and sale of traditional Chinese medicine, Western medicine, healthcare products, and investment holding. It operates in two segments, namely the Chinese Medicine segment and the Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures Western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese medicine.
74GF Score
Get the complete analysis for STU:2TZ
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2TZ has been successfully added to your 
